Cargando…

Why cure, why now?

Combination antiretroviral therapy (cART) is highly effective at preventing morbidity and mortality due to infection with human immunodeficiency virus (HIV), but does not eradicate the virus. Consequently, cART must be administered life-long. Recent progress has stimulated research towards a cure of...

Descripción completa

Detalles Bibliográficos
Autor principal: Kuritzkes, Daniel R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293855/
https://www.ncbi.nlm.nih.gov/pubmed/27273887
http://dx.doi.org/10.1136/medethics-2015-103113
_version_ 1782505145008914432
author Kuritzkes, Daniel R
author_facet Kuritzkes, Daniel R
author_sort Kuritzkes, Daniel R
collection PubMed
description Combination antiretroviral therapy (cART) is highly effective at preventing morbidity and mortality due to infection with human immunodeficiency virus (HIV), but does not eradicate the virus. Consequently, cART must be administered life-long. Recent progress has stimulated research towards a cure of HIV infection. Approaches under investigation include hematopoietic stem cell transplantation, latency reactivating agents, immune based therapies, and cell-based therapies. Each of these approaches carries potential risks that must be weighed against the availability of safe and effective cART. Balancing the risks and benefits of this research poses unique challenges to potential study participants, clinicians and investigators.
format Online
Article
Text
id pubmed-5293855
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-52938552017-02-27 Why cure, why now? Kuritzkes, Daniel R J Med Ethics Background Combination antiretroviral therapy (cART) is highly effective at preventing morbidity and mortality due to infection with human immunodeficiency virus (HIV), but does not eradicate the virus. Consequently, cART must be administered life-long. Recent progress has stimulated research towards a cure of HIV infection. Approaches under investigation include hematopoietic stem cell transplantation, latency reactivating agents, immune based therapies, and cell-based therapies. Each of these approaches carries potential risks that must be weighed against the availability of safe and effective cART. Balancing the risks and benefits of this research poses unique challenges to potential study participants, clinicians and investigators. BMJ Publishing Group 2017-02 2016-06-07 /pmc/articles/PMC5293855/ /pubmed/27273887 http://dx.doi.org/10.1136/medethics-2015-103113 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Background
Kuritzkes, Daniel R
Why cure, why now?
title Why cure, why now?
title_full Why cure, why now?
title_fullStr Why cure, why now?
title_full_unstemmed Why cure, why now?
title_short Why cure, why now?
title_sort why cure, why now?
topic Background
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293855/
https://www.ncbi.nlm.nih.gov/pubmed/27273887
http://dx.doi.org/10.1136/medethics-2015-103113
work_keys_str_mv AT kuritzkesdanielr whycurewhynow